Multicenter phase II trial of combination chemotherapy with weekly paclitaxel and 5-fluorouracil for the treatment of advanced or recurrent gastric carcinoma

Journal of Chemotherapy

Volumn 19, Issue 4, 2007, Pages 444-450

  Ninomiya, M ^a   Kondo, K ^b   Matsuo, K ^c   Hirabayashi, N ^d   Kojima, H ^e   Kobayashi, M ^f   Kawamura, S ^g   Ando, T ^h   Musha, N ⁱ   Konno, H ^j   Nagata, N ^k   Usuki, H ^l   Miyashita, Y ^e   Oba, Koji ^m   Morita, S ⁿ   Sakamoto, J ⁿ  

^a HIROSHIMA CITY HOSPITAL   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^c Shimonoseki Munic Central Hospital   (Japan)

^d HIROSHIMA CITY ASA HOSPITAL   (Japan)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

^f KOCHI UNIVERSITY   (Japan)

^g Graduate School of Health Sciences   (Japan)

^h Hata Prefectual Hospital   (Japan)

ⁱ Saiseikai Niigata Daini Hospital   (Japan)

^j HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^l KAGAWA UNIVERSITY HOSPITAL   (Japan)

^m KYOTO UNIVERSITY   (Japan)

ⁿ NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

5 fluorouracil; Advanced gastric cancer; Clinical trials; Multicenter clinical trial; Paclitaxel

Indexed keywords

FLUOROURACIL; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTHRITIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; FEVER; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIMARY HEALTH CARE; RASH; RECOMMENDED DRUG DOSE; RECURRENT CANCER; SENSORY NEUROPATHY; SIDE EFFECT; STOMACH CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 34547808304     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2007.19.4.444     Document Type: Article

References (30)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Cullinan SA, Moertel CG, Fleming TR, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Huorouracil versus fluorouracil and doxorubicin versus fluorouracil, doxorubicin, and mitomycin. JAMA 1985;253(14): 2061-2067.
3. Leichman L. Gastric cancer therapy; a translational research paradigm. ASCO educational book 1997: 262-271.
4. Murad AM, Santiago FF, Petroianu A. et al. Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer 1993; 72(1): 37-41.
5. Wils JA, Klein HO, Wagener DJ, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin - a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991; 9(5): 827-831.
6. Cascinu S, Labianca R, Alessandroni P, et al. Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. J Clin Oncol 1997; 15(11): 3313-3319.
7. Kelsen D, Atiq OT, Saltz L, et al. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 1992; 10(4): 541-548.
8. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15(1): 261-267.
9. Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose mithotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18(14): 2648-2657.
10. Ajani JA, Van Cutsem E, Moiseyenko V, et al. Docetaxel (D), cisplatin, 5-fluorouracil compared to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naïve patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): interim results of a randomized phase III trial (V325). Proc Am Soc Clin Oncol 2003; 22: 249.
11. Koizumi W, Kurihara M, Sasai T, et al. A phase II study of combination therapy witn 5′-deoxy-5-fluorouridine and cisplatin in the treatment of advanced gastric cancer with primary foci. Cancer 1993; 72(3): 658-662.
12. Shimada Y, Yoshida S, Ohtsu A, et al. A phase II study of EAP (etoposide, adriamycin and cisplatin) in the patients with advanced gastric cancer: Multi-institutional study. J Jpn Soc Cancer Ther 1991; 26: 280.
13. Ohtsu A, Shimada Y, Yoshida S, et al. Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: report from the Japan Clinical Oncology Group (JCOG). Eur J Cancer 1994; 30A(14): 2091-2093.
14. Cullinan SA, Moertel CG, Fleming TR, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, dixorubicin, and mitomycin. JAMA 1985; 253(14): 2061-2067.
15. Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003;21(1): 54-59.
16. Koizumi W, Tanabe S, Higuchi K, et al. Controversial issues in chemotherapy for inoperable gastric cancer (in Japanese). Gan To Kagaku Ryoho 2003; 30(9): 1249-1255.
17. Takiuchi H, Goto M, Kawabe S, Ohta S, Katsu K. Second-line chemotherapy in gastric cancer (in Japanese). Gan To Kagaku Ryoho 2005; 32(1): 19-23.
18. Kondo K, Kobayashi M, Kojima H, et al. Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer. Jpn J Clin Oncol 2005; 35(6): 332-337.
19. Webb A, Cunningham D, Scarffe JH, et al. A randomized trial comparing ECF with FAMTX in advanced oesophago-gastric cancer [Abstract]. Ann Oncol 1996; 7(suppl): 50.
20. Ajani JA, Fairweather J, Dumas P, et al. Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 1998; 4(4): 269-274.
21. Ohtsu A, Boku N, Tamura F, et al. An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol 1998; 21(4): 416-419.
22. Yamaguchi K, Tada M, Horikoshi N, et al. Paclitaxel Gastric Cancer Study Group in Japan : Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer. Gastric Cancer 2002; 5(2): 90-95.
23. Sakamoto J, Morita S, Yumiba T, et al. Ascitic Gastric Cancer Study Group of the Japan South West Oncology Group. A phase II clinical trial to evaluate the effect of paclitaxel in patients with ascites caused by advanced or recurrent gastric carcinoma: a new concept of clinical benefit response for non-measurable type of gastric cancer. Jpn J Clin Oncol 2003; 33(5): 238-240.
24. Shin SJ, Chun SH, Kim KO, et al. The efficacy of paclitaxel and cisplatin combination chemotherapy for the treatment of metastatic or recurrent gastric cancer: a multicenter phase II study. Korean J Intern Med 2005; 20(2): 135-140.
25. Park SR, Oh DY, Kim DW, et al. A multi-center, late phase II clinical trial of Genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer. Oncol Rep 2004; 12(5): 1059-1064.
26. Ueda Y, Yamagishi H, Ichikawa D, et al. Phase I study of a combination of S-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer. Oncology 2005; 69(3): 261-268.
27. Kollmannsberger C, Quietzsch D, Haag C, et al. A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 2000; 83(4): 458-462.
28. Honecker F, Kollmannsberger C, Quietzsch D, et al. Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. Anticancer Drugs 2002; 13(5): 497-503.
29. Yeh KH, Lu YS, Hsu CH, et al. Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer. Oncology 2005; 69(1): 88-95.
30. Kondo K, Kobayashi M, Kojima H, et al. Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer. Jpn J Clin Oncol 2005; 35(6): 332-337.